Condition: Juvenile Open Angle Glaucoma · Dry Eye Disease (DED) · Interleukin 6 · Sponsor: Universiti Sains Malaysia
The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.
This description comes directly from the study's public registry record.
Thamarai Munirathinam, MD(Prague) · +60177712935 · nitaraicz88@gmail.com
Azhany Yaakub, MD, MMed, PhD · azhany@usm.my
Always discuss trial participation with your own doctor first.
| Hospital Raja Perempuan Zainab II | Kota Bharu, Kelantan, Malaysia | Recruiting |
| Hospital Sultan Ismail Petra | Kuala Krai, Kelantan, Malaysia | Recruiting |
| Hospital Universiti Sains Malaysia | Kubang Kerian, Kelantan, Malaysia | Recruiting |
| Hospital Sultanah Nur Zahirah | Kuala Terengganu, Terengganu, Malaysia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07396441